<DOC>
	<DOCNO>NCT01964196</DOCNO>
	<brief_summary>This study evaluate safety dose-response ASP1517 treatment anemia non-dialysis Chronic Kidney Disease ( CKD ) patient ASP1517 apply intermittently .</brief_summary>
	<brief_title>ASP1517 Phase 2 Clinical Trial - Double-Blind Study ASP1517 Treatment Anemia Chronic Kidney Disease Patients Not Dialysis-</brief_title>
	<detailed_description>To evaluate safety dose-response ASP1517 Hemoglobin ( Hb ) correction treatment anemia non-dialysis Chronic Kidney Disease ( CKD ) patient ASP1517 apply intermittently . Patients receive ASP1517 three time week ( TIW ) first 6weeks . Patients may second-randomization TIW dose once-a-week ( QW ) dose Week 6 , 8 , 10 , 12 , 14 16 patient meet criterion .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Chronic kidney disease estimate glomerular filtration rate ( calculate Japanese GFR estimation equation ) = &lt; 89 mL/min/1.73 m2 , require dialysis 3 month since study completion The mean two Hb value screen test Hb test ( least one week apart form screen test ) &lt; 10.0 g/dL , difference ≤1.0 g/dL two value Both TSAT &gt; =5 % ferritin &gt; =30 ng/mL screen test Serum folate ≥4.0 ng/mL Vitamin B12 ≥180 pg/mL screen test Proliferative retinopathy , agerelated macular degeneration , retinal vein occlusion and/or macular edema consider require treatment Immunological disease severe inflammation assess Investigator ; even inflammation remission , subject exclude ( e.g . lupus erythematosus , rheumatoid arthritis , Sjogren 's syndrome , celiac disease , etc ) . Having history gastric/intestinal resection consider influential absorption drug gastrointestinal tract evidence active gastroparesis . Uncontrollable hypertension ( one third blood pressure value diastolic BP &gt; 100 mmHg within 16 week prior screen test include ) Congestive heart failure ( NYHA classification III high ) Having history hospitalization stroke , myocardial infarction lung infarction within 24 week screen test Positive following : antihepatitis C virus antibody ( antiHCV Ab ) ; hepatitis B surface antigen ( HBsAg ) ; human immunodeficiency virus ( HIV ) Anemia anemia due low/absent renal production EPO ( e.g. , iron deficiency anemia , hemolytic anemia , pancytopenia , etc ) Using ESA , anabolic androgenic steroid , testosterone enanthate mepitiostane within 6 week screen test</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Renal anemia</keyword>
	<keyword>Chronic Renal Failure</keyword>
	<keyword>ASP1517</keyword>
</DOC>